{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:55:35Z","timestamp":1790474135450,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.lungcan.2005.05.007","type":"journal-article","created":{"date-parts":[[2005,7,7]],"date-time":"2005-07-07T10:03:38Z","timestamp":1120730618000},"page":"75-82","source":"Crossref","is-referenced-by-count":20,"title":["A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma"],"prefix":"10.1016","volume":"50","author":[{"given":"T.","family":"Berghmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Lafitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Paesmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Stach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Berchier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wackenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Collon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Sculier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lungcan.2005.05.007_bib1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1200\/JCO.1994.12.7.1436","article-title":"Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B Phase II study","volume":"12","author":"Vogelzang","year":"1994","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2005.05.007_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02306613","article-title":"Surgically debulked malignant pleural mesothelioma: results and prognostic factors","volume":"4","author":"Pass","year":"1997","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.lungcan.2005.05.007_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1378\/chest.123.2.551","article-title":"Surgical treatment of malignant pleural mesothelioma: a review","volume":"123","author":"van Ruth","year":"2003","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.lungcan.2005.05.007_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.lungcan.2004.11.003","article-title":"Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary","volume":"48","author":"Maziak","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2005.05.007_bib5","unstructured":"Chahinian AP. Treatment of malignant mesothelioma: radiotherapy and chemotherapy. In: Robinson BW, Chahinian AP, editors. Mesothelioma. London: Martin Dunitz; 2002. p. 209\u201322."},{"issue":"3","key":"10.1016\/j.lungcan.2005.05.007_bib6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.1996.14.3.1007","article-title":"Chemotherapy in malignant pleural mesothelioma: a review","volume":"14","author":"Ong","year":"1996","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2005.05.007_bib7","doi-asserted-by":"crossref","first-page":"66S","DOI":"10.1378\/chest.113.1_Supplement.66S","article-title":"A review of chemotherapy trials for malignant mesothelioma","volume":"113","author":"Ryan","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2005.05.007_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0169-5002(02)00180-0","article-title":"Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis","volume":"38","author":"Berghmans","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2005.05.007_bib9","first-page":"245","article-title":"Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis","volume":"1","author":"Berghmans","year":"2003","journal-title":"Cancer Ther"},{"key":"10.1016\/j.lungcan.2005.05.007_bib10","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2005.05.007_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1016\/j.lungcan.2005.05.007_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.lungcan.2005.05.007_bib13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","article-title":"Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials","volume":"23","author":"Fennell","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2005.05.007_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/thorax.2003.009290","article-title":"BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112","volume":"59","author":"Muers","year":"2004","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.lungcan.2005.05.007_bib15","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1002\/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO;2-Q","article-title":"Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma: an Italian Lung Cancer Task Force (FONICAP) Phase II study","volume":"67","author":"Ardizzoni","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2005.05.007_bib16","first-page":"223","article-title":"Chemotherapy with cisplatin, adriamycin, bleomycin and mitomycin C, combined with systemic and intrapleural hyaluronidase in stage II and III pleural mesothelioma","volume":"3","author":"Breau","year":"1993","journal-title":"Eur Respir Rev"},{"issue":"8","key":"10.1016\/j.lungcan.2005.05.007_bib17","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1200\/JCO.1993.11.8.1559","article-title":"Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B","volume":"11","author":"Chahinian","year":"1993","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2005.05.007_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000216501","article-title":"Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura","volume":"11","author":"Henss","year":"1988","journal-title":"Onkologie"},{"issue":"3","key":"10.1016\/j.lungcan.2005.05.007_bib19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/1097-0142(20010801)92:3<650::AID-CNCR1366>3.0.CO;2-0","article-title":"Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)","volume":"92","author":"Parra","year":"2001","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2005.05.007_bib20","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<1897::AID-CNCR9>3.0.CO;2-D","article-title":"Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force","volume":"79","author":"Pennucci","year":"1997","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2005.05.007_bib21","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/1097-0142(19951201)76:11<2230::AID-CNCR2820761108>3.0.CO;2-2","article-title":"Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma","volume":"76","author":"Shin","year":"1995","journal-title":"Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500205002473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500205002473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T12:17:43Z","timestamp":1551788263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500205002473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0169500205002473"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2005.05.007","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}